Submit Deal

REPLAY HOLDINGS

Summary

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 46 M

Avg. Deal Size£ 46 M

Market Context

Senior Management

Lachlan MacKinnon
CEO
Adrian Woolfson
Executive Chairman, President, and Co-founder

Sort

25 Jul 2022|United Kingdom|Pharmaceuticals

Target: REPLAY HOLDINGS

Bidder: KKR & CO

6 Service Providers

2 Target | 4 Bidder

11 Dealmakers

6 Target | 5 Bidder

£ 45 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy